Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 15;106:111–118. doi: 10.1016/j.biomaterials.2016.08.018

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — Preparation and characterizations of sVLPs. (A) Visualization of nanoparticle solutions following incubation with and isolation from different concentrations of IBV spike proteins. (B) TEM visualization of nanoparticles prepared with a low protein concentration (1000 μg/mL; left) and sVLPs prepared with a high protein concentration (3000 μg/mL; right). Scale bars = 1 μm. (C) Particle-by-particle examination of AuNPs, sVLPs, and native IBV virions under nanoparticle tracking analysis. (D) Size and zeta potential of AuNPs, sVLPs, and native IBV virions as analyzed by nanoparticle tracking analysis. Bars represent means ± s.d. (n = 3). (E) sVLP stability in PBS observed over 7 days. Bars represent means ± s.d. (n = 3). (D) Western blotting analysis confirms the presence of IBV spike proteins on sVLPs. (E) Transmission electron microscopy of sVLPs (left) and native IBV virions (right) following immunogold staining against IBV spike proteins. Scale bars = 50 nm. (H) Western blotting analysis of IBV spike protein retention on sVLPs following different incubation periods in PBS or in 10% BSA.